Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Baylor College of Medicine
Study ID
NCT01940757
Phase
PHASE1
Status
Recruiting

Conditions

  • Hookworm Infection

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Necator americanus Hookworm Larvae — BIOLOGICAL
    Infectious larvae of the human hookworm Necator americanus

Study Details

An experimental hookworm infection model is being developed to provide early proof-of-concept that a hookworm vaccine targeting the blood-feeding pathway of adult hookworms is feasible and efficacious. The proposed model consists of vaccinating healthy, hookworm-naïve adults with a candidate hookworm vaccine, followed by challenging them with the investigational product, Necator americanus Larval Inoculum to assess the effect of vaccination on infection. The first proposed study will be a feasibility study that will consist of administering different doses of the Necator americanus Larval Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of infectious larvae) that is safe, well-tolerated and results in consistent infection.

Key Dates

Start date
Jan 31, 2015
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
35 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Cohort 1 (25 Necator americanus Hookworm Larvae)
    A dose of 25 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.
  • Experimental: Cohort 2 (50 Necator americanus Hookworm Larvae)
    A dose of 50 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.
  • Experimental: Cohort 3 (75 Necator americanus Hookworm Larvae)
    A dose of 75 Necator americanus Hookworm Larvae, administered via a sterile absorbent pad fixed with a transparent adhesive dressing for at least 1 hour.

Primary Outcome Measure

Study product-related adverse events [ Time Frame: Up to 6 months after dosing ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
George Washington University Medical Faculty AssociatesWashington D.C.District of Columbia20037
Study Coordinator
2029941599
Aimee Desrosiers, PA (SUB_INVESTIGATOR)
Elissa Malkin, DO, MPH (SUB_INVESTIGATOR)
Caroline Thoreson, PA (SUB_INVESTIGATOR)

Find similar trials in Washington D.C., DC